PROCEPT BioRobotics: board expands to 10 members, adds Dr. Michael Mack

What happened PROCEPT BioRobotics filed an 8-K stating that on Oct 2, 2026 the board approved (i) an increase in the size of the Board from 9 members to 10 members and (ii) appointed Dr. Michael Mack as a new member of the Board, effective immediately. Dr. Mack was classified as a Class II director and his initial term will expire at the Company’s 2029 annual meeting of stockholders. The Board determined that Dr. Mack is an “independent director” under SEC and Nasdaq rules.

The filing states that Dr. Mack is a cardiac surgeon who has practiced in Dallas, Texas since 1982, is board-certified in internal medicine, general surgery and thoracic surgery, and holds leadership roles including Chairman of the Board of the Baylor Scott & White Research Institute and Chair of the American Board of Thoracic Surgery. Dr. Mack will be compensated consistent with the Company’s other non-employee directors as described in the Company’s definitive proxy statement filed Apr 22, 2026 and will enter into the standard director and officer indemnification and advancement agreement referenced in the filing.

Key details

• Board action date: Oct 2, 2026.
• Board size changed from 9 members to 10 members.
• Dr. Michael Mack designated Class II; initial term expires at the 2029 annual meeting.
• Compensation: consistent with other non-employee directors per the Company’s Apr 22, 2026 proxy; will enter into the Company’s standard indemnification agreement.

Why it may matter This item was reported under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors), which covers changes to the composition of the board of directors. A filing does not show why the insider traded or why the company acted.